Literature DB >> 26598500

The Usefulness of Preoperative Thyroid-Stimulating Hormone for Predicting Differentiated Thyroid Microcarcinoma.

Rong-Liang Shi1, Tian Liao2, Ning Qu2, Fei Liang3, Jia-Ying Chen2, Qing-Hai Ji4.   

Abstract

OBJECTIVE: Thyroid-stimulating hormone (TSH) is a known thyroid growth factor, but the pathogenic role of TSH in thyroid tumorigenesis is controversial. The aim of this study is to examine the relationship between preoperative TSH and differentiated thyroid microcarcinoma (DTMC). DATA SOURCES: We searched PubMed, EMBASE, Ovid, Web of Science, and the Cochrane Library from their inception to March 2015 and performed a systematic literature review of original studies. REVIEW
METHODS: Published studies that explored the relationship between preoperative TSH and DTMC were included for the review. We calculated odds ratio referring to different TSH concentrations between DTMC and control groups and used random effects model for the meta-analysis.
RESULTS: Nine eligible studies that included 6523 patients were identified. Meta-analysis revealed that DTMC was associated with high TSH concentration (odds ratio = 1.23, 95% confidence interval = 1.03-1.46, P = .001). Metaregression analysis indicated that the disparity of control groups was the possible factor resulting in heterogeneity among the studies.
CONCLUSIONS: The risk of DTMC increases significantly in parallel with TSH concentration. These results support the hypothesis that TSH is involved in tumorgenesis of differentiated thyroid cancer. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  differentiated thyroid cancer; microcarcinoma; risk; thyroid-stimulating hormone

Mesh:

Substances:

Year:  2015        PMID: 26598500     DOI: 10.1177/0194599815618388

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

Review 1.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

2.  Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Ozdemir; Cevdet Aydın; Nagihan Bestepe; Serap Ulusoy; Nuran Sungu; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2018-01-27       Impact factor: 3.633

3.  Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.

Authors:  Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  Mol Carcinog       Date:  2016-06-14       Impact factor: 4.784

4.  Predictive Values of Inflammation-Related Markers and Thyroid Function in Pediatric Thyroid Cancer Patients.

Authors:  Shuo Li; Yihao Liu; Shaoxuan Liu; Gongbo Du; Zipeng Wang; Detao Yin
Journal:  Front Pediatr       Date:  2021-12-24       Impact factor: 3.418

5.  The Effect of ThyroidߚStimulating Hormone on Stage of Differentiated Thyroid Carcinoma.

Authors:  Laya Soleimanisardoo; Mohsen Rouhani; Fatemeh Soleymani Sardoo; Mohammad Hossein Gozashti
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.